Azacitidine + Abatacept for T-Cell Lymphoma

This trial explores the potential of two drugs, azacitidine and abatacept, to treat T-cell lymphoma, a type of blood cancer affecting the immune system. Researchers aim to determine if combining these drugs can effectively shrink tumors in patients whose lymphoma has returned or did not respond to initial treatments. Participants receive these medications in cycles, with regular clinic visits and follow-up tests. Suitable candidates for this trial have T-cell lymphoma that hasn't responded to previous treatments or has recurred. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new combination therapy.

The trial does not specify if you need to stop taking your current medications. However, you cannot have had anti-cancer therapy or investigational therapy within 2 weeks before starting the trial. It's best to discuss your current medications with the trial team.

Research has shown that azacitidine is safe and well-tolerated in treatments for other conditions, with promising survival rates. Abatacept has also undergone safety testing in many patients with high-risk blood cancers. Although specific side effects were not mentioned, previous studies suggest it is generally well-tolerated.

Researchers are excited about the combination of azacitidine and abatacept for T-cell lymphoma because it offers a new approach to treatment by targeting the immune system differently. Azacitidine is known for its ability to alter DNA methylation, potentially reversing abnormal gene expressions in cancer cells, while abatacept modulates the immune response by interfering with T-cell activation. This dual-action approach could provide a more effective treatment by directly impacting both the cancer cells and the body's immune system, offering hope for patients who may not respond well to existing chemotherapy and targeted therapies.

Research has shown that azacitidine may effectively treat T-cell lymphoma. In some studies, 50% of patients showed no signs of cancer after treatment, and 25% experienced significant tumor reduction. Abatacept, typically used for autoimmune diseases, helps control the immune system and might also manage cancer growth. This trial will explore the combination of azacitidine and abatacept, with participants receiving either escalating/de-escalating doses or the maximum tolerated dose. Early evidence suggests that combining azacitidine with abatacept may shrink tumors in people with T-cell lymphoma, offering a new option for those whose cancer has returned or hasn't responded to other treatments.¹³⁴⁵⁶